Menactra Vaccine, also called meningococcal conjugate vaccine, is manufactured by Sanofi Pasteur. The Menactra Vaccine claim is that it protects against four types of Neisseria meningitides, the bacteria that cause a significant percent of meningococcal infections, including meningitis. Meningitis is an inflammation of linings of the brain and spinal cord. These bacteria can also cause meningococcemia, a form of blood infection.
Meningococcal infections are potentially life threatening. Approximately 10–14 percent of the cases are fatal, while 11–19 percent of survivors are permanently disabled. The infections are rare, but concern was raised about meningococcal infections in 2000 and 2001 when several American teens died from them. After FDA (Federal Drug Administration) approval of the Menactra Vaccine in January 2005, the Centers for Disease Control and Prevention (CDC) recommended the vaccine for 11- and 12-year-olds, students entering high school, college freshmen planning to live in dormitories, and other groups.
On October 3, 2005 the FDA and CDC alerted consumers and health care providers that they had received five reports of Guillain Barre Syndrome (GBS) following administration of the vaccine. GBS is a serious neurological disorder that can produce paralysis and permanent neurological damage. The FDA and CDC are studying reports of GBS to determine is GBS is a Menactra Vaccine side effect.
Check out the following articles for more information about Menactra Vaccine, filing a Menactra Vaccine lawsuit and finding a Menactra Vaccine attorney.
To learn more about dangerous drugs and the law, go to FreeAdvice.com.